Nom du produit:7-bromo-2-(1-methylpyrazol-4-yl)quinoxaline
IUPAC Name:7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline
- CAS：1083325-87-4
- Formule moléculaire：C12H9BrN4
- Pureté：95%+
- Numéro de catalogue：CM327356
- Poids moléculaire：289.14
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1083325-87-4
- Formule moléculaire:C12H9BrN4
- Point de fusion:-
- Code SMILES:CN1N=CC(C2=NC3=CC(Br)=CC=C3N=C2)=C1
- Densité:
- Numéro de catalogue:CM327356
- Poids moléculaire:289.14
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyrazoles
- Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
- Pyrazone
- Custom pyrazone for customers from all over the world are our main business.
- Quinoxalines
- Quinoxalines, also known as benzopyrazines, are heterocyclic compounds containing a ring complex consisting of a benzene ring and a pyrazine ring. It has isomerism with other naphthalene compounds such as quinazoline, phthalazine, cinnamine, etc. Fusion N-heterocyclic compounds are widely used as valuable entities for the expansion of important pharmacological agents and are considered to be an advantageous scaffold material. Among the numerous fused N-heterocyclic compounds, cinnoline, quinoxaline and quinazoline are important pharmacological agents. In medicinal chemistry, these N-heterocyclic compounds have a wide range of biological properties and can be used as synthetic intermediates, potential drug candidates and chemical probes.
Column Infos
- Erdafitinib
- The Janssen Pharmaceutical Companies of Johnson & Johnson announced on September 8, 2023, that it had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) to seek approval of Erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-[L]1) inhibitor.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
